Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00111956

Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome

Sponsor: Massachusetts General Hospital

Updated 6 times since 2017 Last updated: Oct 4, 2017 Started: Apr 30, 2004 Primary completion: May 31, 2005 Completion: May 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00111956, this PHASE2/PHASE3 trial focuses on Metabolic Syndrome X and remains completed. Sponsored by Massachusetts General Hospital, it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Oct 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

Phase: NA → PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Oct 2017 [monthly]

Completed NA

First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Massachusetts General Hospital
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Data source: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States